Manus began in 2011 with a contrarian idea from an MIT lab: that an engineered microbe could make a plant's most valuable molecule more productively than the plant itself. Fourteen years later, that idea has hardened into steel tanks in Augusta, Georgia.
Manus - legally Manus Bio, Inc. - is an industrial biotechnology company. It designs microbial "cell factories" and runs them through precision fermentation to produce natural ingredients that are otherwise extracted from crops or synthesized from petrochemicals. The company brands itself as "The BioAlternatives Company," a phrase meant less as a slogan than as a job description: find an ingredient that is expensive, scarce or environmentally costly to source, and rebuild its supply chain inside a living cell.
The founding team pairs a chemist-entrepreneur, Ajikumar Parayil, with one of the field's academic pillars, MIT professor Gregory Stephanopoulos, widely regarded as a pioneer of metabolic engineering. Around them, a group of MIT biochemical engineers set out to close a specific gap - the sustainable sourcing of chemicals and ingredients - using biology rather than agriculture or oil.
What Manus actually sells is deceptively ordinary: sweetness and flavor. Its monk fruit sweetener is, by the company's account, the first produced at commercial scale in the United States. Its Yume M stevia is described as the first large-scale commercialization of an all-Americas sourced and bioconverted Reb M. Neither product requires the fruit or the leaf - the sweet molecules are brewed by microbes fed on sugar, then purified.
The customers are business buyers, not shoppers. Flavor-and-fragrance houses, food and beverage brands, and nutrition companies buy Manus ingredients or hire the company to develop and manufacture their own. Givaudan, one of the largest flavor companies in the world, worked with Manus on BioNootkatone, a grapefruit note. Tate & Lyle has been named in its sweetener work. The name "Manus" - Latin for "hand" - is a nod to that hands-on, make-it-real posture.
Manus frames its central challenge as biotech's "Valley of Death," the treacherous gap between a promising lab result and a product that ships on time, at spec, at cost. Its answer is structural: a research hub in Boston for cell-factory engineering, and a large-scale manufacturing plant in Augusta for the unglamorous work of scale-up. The split is the strategy.
That strategy has attracted capital and, more recently, the government. A $75 million Series B in 2020 - led by Thailand's BBGI and co-led by NXT Ventures - funded the Augusta expansion. In 2024 the U.S. Department of Health and Human Services tapped Manus under a Defense Production Act program to help build a domestic source of artemisinin, an anti-malarial ingredient, with funding that has grown to $47.4 million. In May 2026 the company broke ground on that facility, joined by HHS leadership and members of Congress.
